Board Meeting Details
The Board Meeting was held on July 29, 2026, commencing at 03:45 p.m. and concluding at 04:17 p.m.
Financial Results Status
Unaudited financial results for quarter ended June 30, 2026, accompanied by Limited Review Report issued by statutory auditors Walker Chandiok & Co LLP. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410. The auditors concluded that nothing came to their attention causing them to believe the statement contains material misstatement or fails to comply with disclosure requirements of Regulation 33.
Business Segment
The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to customers in India and overseas, considered as a single reportable business segment.
Significant Events and Transactions
Labour Code Implementation Impact
The Government of India consolidated multiple labour legislations into four Labour Codes effective November 21, 2025. This resulted in changes to computation of certain employee benefits. The Company assessed impact in accordance with Ind AS 19 - Employee Benefits and ICAI guidance. An additional employee benefit expense of ₹20.79 million, deemed material and non-recurring, was presented under "Exceptional Items" in financial results for year ended March 31, 2026.
On May 8, 2026, the Central Government notified the Code of Wages (Central) Rules, 2026. The Company is currently evaluating the consequential impact of these Rules and continues to monitor developments pertaining to the Labour Codes.
Employee Stock Option Plan (ESOP) Activity
During the quarter:
- Granted 153,000 stock options to eligible employees as determined by Nomination and Remuneration Committee
- Allotted 473,220 equity shares on exercise of vested stock options by eligible employees
Dividend Recommendation
The Board of Directors, at their meeting held on April 27, 2026, recommended a final dividend of ₹4 per equity share (face value ₹2 each) for the year ended March 31, 2026, subject to approval in Annual General Meeting.
Share Buy-Back
During the quarter, pursuant to approvals of Board of Directors and shareholders, the Company undertook a buy-back of up to 1,600,000 equity shares of ₹2 each at a price of ₹250 per share for an aggregate consideration not exceeding ₹400 million. The buy-back was executed through tender offer route in accordance with Companies Act, 2013 and SEBI (Buy-Back of Securities) Regulations, 2018.
Acquisition Activity
The Company entered into a Share Purchase Agreement on June 29, 2026 to acquire an 85% equity stake in Aequitas Healthcare Private Limited for a consideration of ₹208 million. The acquisition is proposed to be funded through internal accruals. The existing promoters/directors will retain 15% shareholding and continue to manage the business.
While the Share Purchase Agreement was executed during the quarter, the transfer of shares and completion of closing formalities (including execution of completion certificate) were completed subsequently in July 2026. Therefore, the acquisition did not have any impact on the financial results for the quarter ended June 30, 2026.
Financial Figures Reference
The figures for the quarter ended March 31, 2026 (Q4 FY26), as reported in the financial results, are balancing figures between the audited figures for year ended March 31, 2026 and published year-to-date figures for December 31, 2025, which were subjected to limited review by statutory auditors.
Approval Process
The financial results for quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2026.